The Enterprise Value as of December 2024 (TTM) for Kronos Bio, Inc. (KRON) is 8.16M

According to Kronos Bio, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 8.16M. This represents a change of -75.93% compared to the average of 33.89M of the last 4 quarters.

Kronos Bio, Inc. (KRON) Historical Enterprise Value (quarterly & annually)

How has KRON Enterprise Value performed in the past?

The mean historical Enterprise Value of Kronos Bio, Inc. over the last ten years is 645.07M. The current 8.16M Enterprise Value has changed 26.46% with respect to the historical average. Over the past ten years (40 quarters), KRON's Enterprise Value was at its highest in in the September 2020 quarter at 1.52B. The Enterprise Value was at its lowest in in the September 2022 quarter at -49908787.15.

Kronos Bio, Inc. (KRON) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Kronos Bio, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Kronos Bio, Inc. (KRON) Average Enterprise Value

How has KRON Enterprise Value performed in the past?

The current Enterprise Value of Kronos Bio, Inc. (KRON) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Kronos Bio, Inc. (KRON) Enterprise Value vs. Peers

How is KRON’s Enterprise Value compared to its peers?

Kronos Bio, Inc.’s Enterprise Value is greater than Cyclerion Therapeutics, Inc. (5.80M), less than Larimar Therapeutics, Inc. (222.97M), greater than Addex Therapeutics Ltd (7.35M), greater than Achilles Therapeutics plc (-42104641.00), greater than NextCure, Inc. (4.04M), less than CytomX Therapeutics, Inc. (55.32M), greater than Neoleukin Therapeutics, Inc. (-6333315.00), greater than Spero Therapeutics, Inc. (-21358605.00), less than Assembly Biosciences, Inc. (67.83M), less than Replimune Group, Inc. (892.33M), less than Nuvectis Pharma, Inc. (71.32M), less than Lyra Therapeutics, Inc. (22.97M), less than Gossamer Bio, Inc. (369.59M), less than Crinetics Pharmaceuticals, Inc. (4.74B), less than Inhibrx Biosciences, Inc. (14.97M), less than Merus N.V. (2.48B), less than Lyell Immunopharma, Inc. (131.00M), less than Generation Bio Co. (145.59M), less than Erasca, Inc. (685.22M), less than C4 Therapeutics, Inc. (294.04M), less than Edgewise Therapeutics, Inc. (2.80B),

Build a custom stock screener for Kronos Bio, Inc. (KRON) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kronos Bio, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Kronos Bio, Inc. (KRON) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Kronos Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.